{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-170572","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.691466+00:00","generated_at":"2026-05-15T04:54:11.243552+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Quince Therapeutics appoints June Bray as independent director, expands board to four members","bullets":["June Bray appointed as Class I director effective April 22, 2026, filling a vacancy on the four-member board.","Bray is deemed independent and will serve on Nominating & Governance, Audit, and Compensation Committees.","Director compensation: $38,000 annual board retainer plus $7,500 (Nominating & Gov), $5,500 (Audit), $4,000 (Comp); no initial option grant.","Bray will enter the company's standard form of indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-170572","json":"https://secwatch.observer/filing/0001193125-26-170572.json","markdown":"https://secwatch.observer/filing/0001193125-26-170572.md","text":"https://secwatch.observer/filing/0001193125-26-170572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526170572/0001193125-26-170572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526170572/d27180d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:54:11.243552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}